TRANSACT Lat ® Flurbiprofen

TRANSACT Lat ® is a Flurbiprofen based drug

THERAPEUTIC GROUP: Non-steroidal anti-inflammatory drugs for topical use.

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications TRANSACT Lat ® Flurbiprofen

TRANSACT Lat ® is successfully used in the treatment of local painful states based on inflammation of the musculoskeletal system.

Mechanism of action TRANSACT Lat ® Flurbiprofen

TRANSACT Lat ® is a medicated plaster, characterized by important pharmacokinetic properties, particularly suitable for treating local pain states on an inflammatory basis.

More precisely, the transdermal absorption with relative accumulation in the subcutis of the flurbiprofen active principle on the one hand and the reduced blood concentrations that the active principle in question reaches from the other, allow the medicinal product to carry out an analgesic and anti-inflammatory action concentrated in the application site, avoiding the systemic effects, many of which are adverse, associated with the common non-steroid enteral anti-inflammatory therapy.

From the pharmacodynamic point of view, on the other hand, flurbiprofen, a molecule derived from phenylproprionic acid, maintains the typical characteristics of NSAIDs, exerting the anti-inflammatory action through the inhibition of cyclooxygenases, and in particular of the second cyclooxygenase, responsible for the production of mediators with pro-inflammatory activity such as prostaglandins and prostacyclins.

The therapeutic action of TRANSACT Lat ® is also completed by the analgesic activity exerted by the active principle both at the peripheral and central level, through non-opioid mechanisms that provide a modulation mechanism for receptor activity.

After its activity, flurbiprofen, following hydroxylation processes, is eliminated in the form of hydroxyflurbiprofen with urine.

Studies carried out and clinical efficacy

1.IPERSENSITIVITY TO FLURBIPROPHENE

J Intern Med. 1997 Jan; 241 (1): 81-3.

Case report demonstrating an occasional hypersensitivity reaction to topical flurbiprofen with the development of a maculopaular rash, followed by angioedema and hypotension in the subsequent 48 hours, thus suggesting a fourth type hypersensitivity.

2. THE FLURBIPROPHENES IN THE TREATMENT OF RHEUMATISMS OF SOFT TISSUES

Clin Rheumatol. 1997 Jan; 16 (1): 25-31.

Work demonstrating the greater efficacy of local treatment with flurbiprofen in patch rather than oral diclofenac in the short-term (2 weeks) therapy of soft tissue rheumatism. In addition to the greater efficacy it is also important to point out the excellent tolerability of the therapy.

3. FLURBIPROPHEN IN RADIOTHERAPY MUCOSITIS

Support Care Cancer. 2005 Jan; 13 (1): 42-8. Epub 2004 Sep 9.

Study demonstrating the ineffectiveness of flurbiprofen in preventing mucositis following radiotherapy foreseen for the treatment of head-neck cancer, which is often associated with a proliferative increase in basal epithelial cells of the oral mucosa, with significant histological changes.

Method of use and dosage

TRANSACT Lat ®

Flurbiprofen 40 mg medicated plasters.

Given the amount of active ingredient contained in a plaster and the half-life of flurbiprofen, we recommend the application of a medicated plaster every 12 hours.

The application must be carried out on intact and clean skin, free of obvious lesions and excluding direct contact with the mucous membranes.

If the inflammatory state concerns particularly mobile joints, we recommend the use of a containing bandage, in order to keep TRANSACT Lat ® in place.

Warnings TRANSACT Lat ® Flurbiprofen

Although taking flurbiprofen topically significantly reduces the risk of adverse events, the patient should consult his doctor before using TRANSACT Lat ®.

It is also necessary to ascertain the integrity of the skin and the absence of continuity solutions in the region where the patch will be applied, in order to avoid significant variations in the pharmacokinetic characteristics expected for this type of medicine.

Face the risk of photosensitivity, associated with topical application of flurbiprofen, it is recommended to avoid exposure to sunlight, following the use of the patch.

The appearance of side effects should alarm the patient, who after having heard his doctor, might be inclined to suspend the therapy in progress.

PREGNANCY AND BREASTFEEDING

Given the biological role of prostaglandins during embryonic and fetal development and given the absence of studies able to ascertain the safety profile of TRANSACT Lat ® on fetal and infant health, the use of this medicine is not recommended. during pregnancy and during the subsequent breastfeeding period.

Interactions

Although the use of topical NSAIDs significantly reduces all the possible interactions described instead for the product taken by mouth, it is advisable to avoid the simultaneous use of other non-steroidal anti-inflammatory drugs in order to reduce the incidence of adverse events, above all on of the gastro-intestinal mucosa.

Contraindications TRANSACT Lat ® Flurbiprofen

The use of TRANSACT Lat ® is contraindicated in patients who are hypersensitive to the active ingredient, its excipients and structurally related molecules, in patients with previous history of photosensitivity or suffering from active phase peptic ulcers and dermatological diseases.

Undesirable effects - Side effects

The low plasma concentrations of flurbiprofen, which are observed following the use of TRANSACT Lat ®, make it possible to significantly limit the potential side effects generally associated with NSAID therapy.

However, the application of the patch may in some cases determine the site of interest, itching, redness, mild paraesthesia and erythema.

It is essential to remember that non-steroidal anti-inflammatory drugs can increase the risk of photosensitivity of the treated skin region.